Olema Pharmaceuticals, Inc.
OLMA
NASDAQ·Healthcare·Biotechnology·Mkt cap $939.0M
$10.75
▲ +0.19%
P/E
-5.05
Mkt Cap
$939.0M
52-Wk Range
$6.65–$36.26
52-Week Range
$6.65 - $36.26
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Up 41.8% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Dual-mechanism OP-1250 candidate with ER antagonist and selective ER degrader properties
- Focused pipeline strategy targeting underserved women's cancer indications
- Clinical-stage validation of novel mechanism of action in hormone receptor-positive breast cancer
Bear Case
1 risk
- Above-average volatility (beta 2.0).
Growth
Stable outlook
Advancement of OP-1250 through Phase 1/2 clinical trials toward Phase 3 development
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Strong
+7.9% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying OLMA right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 9, 2026
AUG 10, 2026
Reported EPS of -$0.61 vs -$0.55 consensus (-10.6% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-10.6%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
5 analysts · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Citi · Aug 11, 2026
vs Industry
How OLMA stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related